Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with immune-mediated inflammatory diseases receiving Janus kinase inhibitors: A comparative cohort study
Enfermedades Infecciosas y Microbiología Clínica · 2027-01 · 45 (1) · 503367
DOI: 10.1016/j.eimc.2026.503367 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Enfermedades Infecciosas y Microbiología Clínica, 2027-01. Verfasst von Ana Esteban-Vazquez und 17 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Esteban-Vazquez, A., Steiner, M., Cobo-Ibanez, T., Richi-Alberti, P., Romero-Bogado, L., Vergara-Dangond, C., Acosta, A., Trives, L., Paredes-Romero, M. B., Cámara, I. D. L., Sánchez, R., Puerto, E., Marin, C., Segundo, M. D. S., Sanchis, A., Thuissard, I., Navío, T., & Muñoz-Fernández, S. (2027). Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with immune-mediated inflammatory diseases receiving Janus kinase inhibitors: A comparative cohort study. Enfermedades Infecciosas y Microbiología Clínica, 45(1), 503367. https://doi.org/10.1016/j.eimc.2026.503367
Vancouver
Esteban-Vazquez A, Steiner M, Cobo-Ibanez T, Richi-Alberti P, Romero-Bogado L, Vergara-Dangond C, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with immune-mediated inflammatory diseases receiving Janus kinase inhibitors: A comparative cohort study. Enfermedades Infecciosas y Microbiología Clínica. 2027;45(1):503367. doi:10.1016/j.eimc.2026.503367
BibTeX
@article{EstebanVazquez2027,
author = {Esteban-Vazquez, Ana and Steiner, Martina and Cobo-Ibanez, Tatiana and Richi-Alberti, Patricia and Romero-Bogado, Liz and Vergara-Dangond, Cristina and Acosta, Ana and Trives, Laura and Paredes-Romero, M. Beatriz and Cámara, Isabel De la and Sánchez, Rosa and Puerto, Encarnación and Marin, Carolina and Segundo, Marta De San and Sanchis, Antonio and Thuissard, Israel and Navío, Teresa and Muñoz-Fernández, Santiago},
title = {Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with immune-mediated inflammatory diseases receiving Janus kinase inhibitors: A comparative cohort study},
journal = {Enfermedades Infecciosas y Microbiología Clínica},
year = {2027},
volume = {45},
number = {1},
pages = {503367},
doi = {10.1016/j.eimc.2026.503367}
}
EUVIMED